Navigation Links
Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk
Date:6/6/2009

- Late-Breaking Data from Pivotal BLOOM Trial Presented at the American Diabetes Association's 69th Scientific Sessions Expand on Previously Announced Positive Top-Line Results -

NEW ORLEANS, June 6, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today a late-breaking poster presentation of positive results from BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management), the first of two pivotal trials evaluating the safety and efficacy of lorcaserin for weight management, at the American Diabetes Association's 69th Scientific Sessions. Lorcaserin patients achieved highly significant categorical and absolute weight loss in Year 1, and continued treatment with lorcaserin in Year 2 helped significantly more patients maintain their weight loss as compared to those on placebo. Treatment with lorcaserin also resulted in highly significant improvements as compared to placebo in multiple secondary endpoints associated with cardiovascular risk. Lorcaserin did not result in increased risk of depression and was not associated with the development of cardiac valvular insufficiency.

Previously announced BLOOM data demonstrated that lorcaserin was highly efficacious, achieving statistical significance on all three co-primary efficacy endpoints, and was very well tolerated. The BLOOM results also satisfy the efficacy requirement in the most recent US Food and Drug Administration, or FDA, draft guidance for the development of drugs for weight management.

"These data provide reason for new optimism for the millions of people who struggle with managing their weight and are in need of novel, well tolerated treatments to help improve their overall health," said Steven R. Smith, M.D., Co-Principal Investigator and Professor and Assistant Director for Clinical Research at
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions
2. Arena Pharmaceuticals to Host Conference Call and Webcast on Monday, March 30, 2009 to Discuss Lorcaserin Pivotal Phase 3 Obesity Trial Results
3. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
4. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
5. Critical Pharmaceuticals Enter Sustained Release hGH Arena
6. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
9. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
10. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
11. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 2014 Levi & Korsinsky announces that a ... States District Court for the District of ... Galectin Therapeutics Inc. ("Galectin" or the "Company") (NasdaqCM: GALT) ... For more information, click here: http://zlk.9nl.com/galectin-therapeutics-galt ... Class Period the Company violated federal securities laws by ...
(Date:8/28/2014)... LONDON , Aug. 28, 2014  A candidate ... The Gambia and Mali ... safety trials of potential vaccines aimed at preventing the disease that ... West Africa . Human trials of ... Health (NIH) and GlaxoSmithKline, are to be accelerated with funding from ...
(Date:8/28/2014)... , Aug. 28, 2014 Nonin Medical, Inc., ... in noninvasive medical monitoring, today announced that the Food ... 3231 OEM/eHealth finger pulse oximeter for use in ... oximeter plugs into a telemedicine hub or kiosk through ... rate in pediatric to adult patients. The Model 3231 ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Galectin Therapeutics Inc. and Its Board of Directors and a Lead Plaintiff Deadline of September 29, 2014 -- GALT 2Ebola vaccine trials fast-tracked by international consortium 2Ebola vaccine trials fast-tracked by international consortium 3Ebola vaccine trials fast-tracked by international consortium 4Ebola vaccine trials fast-tracked by international consortium 5Ebola vaccine trials fast-tracked by international consortium 6Ebola vaccine trials fast-tracked by international consortium 7Nonin Medical Announces FDA Clearance of Nonin Model 3231 USB Pulse Oximeter 2
... New study finds patients who opt for surgery have decreased pain, ... with the spine disease called degenerative spondylolisthesis * ... pain over time compared to those who do not have surgery, ... The Journal of Bone and Joint Surgery ...
... GAITHERSBURG, Md., June 1 Overall survival data in ... GenVec,s ongoing Phase III Pancreatic Cancer Clinical Trial with ... Society of Clinical Oncology Annual Meeting in Orlando, FL. ... ) , , The poster ...
Cached Medicine Technology:Back to Normal: Surgery Improves Outcomes for Spine Patients 2Back to Normal: Surgery Improves Outcomes for Spine Patients 3Back to Normal: Surgery Improves Outcomes for Spine Patients 4TNFerade(TM) Phase III Data Presented at ASCO 2TNFerade(TM) Phase III Data Presented at ASCO 3
(Date:8/28/2014)... (PRWEB) August 28, 2014 Save ... Healthbox tech accelerator program in Tampa. Healthbox Florida ... innovative healthcare companies grow and achieve their goals. ... August 16th, at their launch event at the Mahaffey ... professionals. , Co-founder Matt Schneider commented on the Save ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 As September ... the more than 100 million people who suffer from ... from the Committee on Advancing Pain Research, Care, and ... of Health, is defined as any pain lasting more ... longer. And while chronic pain causes range from injury ...
(Date:8/28/2014)... 2014 ISI Telemanagement Solutions, Inc., ... be sponsoring the 2014 Presidio Exchange this September ... Presidio leadership to engage with the community with ... will be rolling out objectives for representatives to ... the event, ISI will be discussing their growing ...
(Date:8/28/2014)... CA (PRWEB) August 28, 2014 Commercial growers ... changing, new Kind K5 series LED grow lights, which perform ... Besides the wattage savings, Kind LED lighting needs no cooling ... room requires less cooling as well. Factoring in that they ... LED lighting is less than a year. , For many ...
(Date:8/28/2014)... 2014 Following the death of an 18-year-old ... FDA issued a warning on powdered caffeine products. ... substance that is readily available to consumers, despite the fact ... senior Logan Stiner died from an overdose of caffeine powder. ... the FDA to issue a safety advisory for caffeine powders. ...
Breaking Medicine News(10 mins):Health News:Save On Medical Accepted Into Healthbox Accelerator Program 2Health News:Interventional Pain Management Expert Glenn M. Lipton, M.D. Shares Common-Sense Tips for Preventing Chronic Pain 2Health News:Interventional Pain Management Expert Glenn M. Lipton, M.D. Shares Common-Sense Tips for Preventing Chronic Pain 3Health News:ISI Telemanagement Solutions, Inc. to Sponsor 2014 Presidio Exchange 2Health News:New Kind K5 Series LED Grow Lights Pave Way for Future of Indoor Gardening 2Health News:FDA Issues Safety Advisory for Caffeine Powders 2
... ... Legal Hold Pro™ service into doeDiscovery™. Further expanding doeLegal,s capabilities across the entire spectrum ... to offer increased value to all eDiscovery clients. , ... (PRWEB) May 14, 2010 -- doeLegal, ...
... at ethical issues arising from new neuroimaging research suggesting ... injury might be able to communicate. Title: Severe ... Andrew Billings, Larry R. Churchill, and Richard Payne, Summary: ... meaningful existence? The authors contend that "modern neuroscience ...
... ... in science , ... New York, NY (Vocus) May 13, 2010 -- Mount Sinai School of Medicine at ... of genetics and human genome research, and renowned humanists whose work has advanced biomedical ...
... ... for its many customers who have been touched by cancer, CIGNA expands access to all ... ... of access, quality and choice for its many customers who have been touched by cancer, ...
... 20 people over age 65, experts note, , THURSDAY, ... common irregular heartbeat known as atrial fibrillation in a ... and other forms of dementia, new research finds. , ... beat chaotically, causing blood to pool and increasing the ...
... blood test could spot those who need more supplementation, ... Seventy percent of pregnant women in the United States ... What,s more, the regimen of prenatal vitamins that many ... to boost levels when needed, researchers from the University ...
Cached Medicine News:Health News:doeLegal and Zapproved Sign Alliance to Add Legal Hold Pro to Suite of Powerful Online Legal Solutions 2Health News:doeLegal and Zapproved Sign Alliance to Add Legal Hold Pro to Suite of Powerful Online Legal Solutions 3Health News:The Hastings Center Report table of contents for May/June 2010 2Health News:The Hastings Center Report table of contents for May/June 2010 3Health News:Mount Sinai School of Medicine Commencement Honors Leaders in Genetics and Global Health 2Health News:Mount Sinai School of Medicine Commencement Honors Leaders in Genetics and Global Health 3Health News:Mount Sinai School of Medicine Commencement Honors Leaders in Genetics and Global Health 4Health News:Mount Sinai School of Medicine Commencement Honors Leaders in Genetics and Global Health 5Health News:Mount Sinai School of Medicine Commencement Honors Leaders in Genetics and Global Health 6Health News:CIGNA and Cancer Treatment Centers of America Reach New Agreement 2Health News:Treating Common Irregular Heartbeat Might Also Ward Off Alzheimer's 2Health News:Treating Common Irregular Heartbeat Might Also Ward Off Alzheimer's 3Health News:Many Pregnant Woman Not Getting Enough Vitamin D 2